Quick Answer
COGNITION THERAPEUTICS INC reported Stockholders Equity of $34.27 million for the year ending 2025.
- COGNITION THERAPEUTICS INC showed an increase of +82.8% in Stockholders Equity from 2024 to 2025.
- This data is from COGNITION THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$61.97 million | Q2 2020: -$64.51 million | Q3 2020: -$66.49 million | Q1 2021: -$67.85 million | Q2 2021: -$83.68 million | Q3 2021: -$86.72 million | Q1 2022: $48.74 million | Q2 2022: $43.90 million | Q3 2022: $39.32 million | Q1 2023: $35.78 million | Q2 2023: $34.39 million | Q3 2023: $28.93 million | Q1 2024: $28.86 million | Q2 2024: $23.01 million | Q3 2024: $14.48 million | Q1 2025: $12.27 million | Q2 2025: $7.03 million | Q3 2025: $36.53 million.
- Over the full 7 years of available data (2019 to 2025), COGNITION THERAPEUTICS INC's Stockholders Equity has grown by 158.7%.
- Historical annual values: Fiscal year 2025: $34.27 million | Fiscal year 2024: $18.75 million | Fiscal year 2023: $24.47 million | Fiscal year 2022: $40.25 million | Fiscal year 2021: $51.27 million | Fiscal year 2020: -$68.18 million | Fiscal year 2019: -$58.42 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: